BOLT (Bolt Biotherapeutics) Float Percentage Of Total Shares Outstanding : 80.11% (As of Dec. 15, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bolt Biotherapeutics's float shares is 30.66 Mil. Bolt Biotherapeutics's total shares outstanding is 38.27 Mil. Bolt Biotherapeutics's float percentage of total shares outstanding is 80.11%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bolt Biotherapeutics's Insider Ownership is 0.35%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bolt Biotherapeutics's Institutional Ownership is 49.77%.

Bolt Biotherapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Bolt Biotherapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	30.66	/	38.27
	=	80.11%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bolt Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (NAS:BOLT) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

6LP:Germany

Address

900 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.boltbio.com

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on our deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

Executives

William P. Quinn	officer: Chief Financial Officer	SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Edgar Engleman	director	575 HIGH STREET, STE 201, PALO ALTO CA 94301
Vivo Capital Fund Viii, L.p.	10 percent owner	505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Laura Berner	director	C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
James Healy	director	3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Brian O'callaghan	director	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Frank D. Lee	director	C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Kathleen Laporte	director
Miller Richard A Md	director	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Mahendra Shah	director	2250 HOLCOMBE BLVD, HOUSTON TX 77030
Grant Yonehiro	officer: Chief Business Officer	C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063
Randall C Schatzman	director, officer: Chief Executive Officer	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
David Dornan	officer: Chief Scientific Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Edith A. Perez	officer: Chief Medical Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063